Biocon/Fujifilm Enter Lantus Biosimilar Fray In Japan
This article was originally published in PharmAsia News
Executive Summary
Biocon and Fujifilm Pharma have received approval for their biosimilar insulin glargine from Japan's Ministry of Health, Labour and Welfare, marking what the Indian firm termed a "huge credibility milestone" and adding further pressure on innovator Sanofi's Lantus.
You may also be interested in...
Biocon Claims Edge For Adalimumab In US
Biocon, which is set to close its deal with Viatris shortly, says it is in a “very good position” to vie for a share of the adalimumab biosimilar pie in the US and has had encouraging preliminary discussions with payers.
Humira Biosimilar Drumbeats: Biocon Claims Edge For Adalimumab In US
Biocon, which is set to close its deal with Viatris shortly, says it is in a “very good position” to vie for a share of the adalimumab biosimilar pie in the US and has had encouraging preliminary discussions with payers.
GC Pharma/Biocon Eye Low Price Strategy As Biosimilar Insulin Glargine Approved In Korea
GC Pharma/Biocon are set to adopt a low price strategy for their biosimilar insulin glargine, which has just received regulatory approval in South Korea, to better compete with rival products.